Corvus Pharmaceuticals's total assets for Q4 2025 were $71.12M, a decrease of -11.62% from the previous quarter. CRVS total liabilities were $9.91M for the fiscal quarter, a 13.88% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.